Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by AB Science
Information provided by (Responsible Party):
AB Science Identifier:
First received: September 12, 2011
Last updated: April 20, 2017
Last verified: April 2017
The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.

Condition Intervention Phase
Multiple Sclerosis, Secondary Progressive
Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Relapse Free
Drug: masitinib
Drug: placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by AB Science:

Primary Outcome Measures:
  • EDSS [ Time Frame: week 96 ]

Secondary Outcome Measures:
  • Multiple Sclerosis Quality of Life 54 items (MSQOL-54) [ Time Frame: week 96 ]
  • Multiple Sclerosis Functional Composite (MSFC) [ Time Frame: week 96 ]

Estimated Enrollment: 450
Study Start Date: August 2011
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: masitinib
masitinib 4.5 mg/kg/day
Drug: masitinib
6 mg/kg/day
Placebo Comparator: placebo Drug: placebo
masitinib matching placebo


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient suffering from either primary progressive or secondary progressive multiple sclerosis without relapse within 2 years before inclusion according to the revised McDonald's criteria
  2. Patient with EDSS score of [2.0 to 6.0] inclusive at baseline
  3. Patient who had an EDSS score progression ≥ 1 point confirmed by a second evaluation carried out at least 6 months apart, within 2 years before inclusion

Exclusion Criteria:

  1. Patient suffering from a disease other than MS that would better explain the patient's neurological clinical signs and symptoms and/or MRI lesions
  2. Patient in who MRI examination and injection of gadolinium contrast agents should not be used
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01433497

Contact: Patrick Vermersch, MD, PhD

Hospital de la Santa Creu i Sant Pau Recruiting
Barcelona, Spain, 08041
Sponsors and Collaborators
AB Science
  More Information

Responsible Party: AB Science Identifier: NCT01433497     History of Changes
Other Study ID Numbers: AB07002
Study First Received: September 12, 2011
Last Updated: April 20, 2017

Keywords provided by AB Science:
multiple sclerosis
primary progressive
secondary progressive

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Neoplasm Metastasis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Neoplastic Processes
Disease Attributes processed this record on May 24, 2017